Bridging the divide: Impact of remote expert oncology opinions on populations facing socioeconomic and geographic inequalities. First-line endocrine-based therapy in metastatic breast cancer: ...

Tumor lysis syndrome (TLS) has recently been subclassified into either laboratory TLS or clinical TLS, and a grading system has been established. Standardized guidelines, however, are needed to aid in ...

Extended ibrutinib and venetoclax therapy improves outcomes in R/R CLL, with a 40% complete response rate and high survival rates. A six-month ibrutinib lead-in reduces tumor burden and tumor lysis ...

Tagraxofusp demonstrated a manageable safety profile but limited efficacy in CMML patients, with stable disease as the best ...

SCLC patients, particularly with high tumor burden, face significant ATLS risk, despite typically low overall risk in solid tumors. Early recognition and aggressive intervention are crucial, yet may ...

RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...

Featuring articles on PI3K-altered colorectal cancer, type 2 diabetes, oral semaglutide, and proportional-assist ventilation; a review article on tumor lysis syndrome; a case report of a girl with ...